Efstathios Kastritis, MD, on Main Takeaways From Trial Examining Daratumumab Plus VCd to Treat AL Amyloidosis

Video
Conference|ASCO Annual Meeting: Hematology

Hematologic responses improved for patients treated with daratumumab plus VCd versus VCd alone in the ANDROMEDA trial.

CancerNetwork® had the opportunity to speak with Efstathios Kastritis, MD, at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting. The professor of medical oncology at the National and Kapodistrian University of Athens, in Athens, Greece, detailed the overall takeaway of the phase 3 ANDROMEDA trial (NCT03201965), specifically how treatment with daratumumab (Darzalex) plus bortezomib, cyclophosphamide, and dexamethasone (VCd) improved outcomes for patients with newly diagnosed light chain (AL) amyloidosis.

Transcription:

We do have a very effective and relatively safe therapy for patients with AL amyloidosis, which has really and substantially improved the outcomes of our patients, [with] both complete hematologic response rates and organ responses, which is actually the ultimate goal of therapy in these patients. I really expect that this will be translated in an improvement in the overall survival in the follow up of this study.

Reference

Kastritis E, Sanchorawala V, Merlini G, et al. Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. Presented at: 2021 ASCO Annual Meeting; June 4-8, 2021; Virtual. Abstract 8003.

Recent Videos
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
relapsed or refractory mantle cell lymphoma, glofitamab, Obinutuzumab, phase 1/2 study, NCT03075696, Tycel J. Phillips, MD
Related Content
Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

Neoadjuvant Sotigalimab Proves Efficacious in Rectal Cancer

Ariana Pelosci
October 3rd 2024
Article

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.

Adjuvant cCRT Improves Disease Control, But Increases AEs in Breast Cancer

Gina Mauro
October 3rd 2024
Article

Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.

Nausheen Ahmed, MD, discusses findings from a study supporting reduced monitoring windows for patients with lymphoma who receive CAR T-cell therapy.

Improving CAR T-Cell Therapy Monitoring Strategies and Access in Lymphoma

Nausheen Ahmed, MD
July 29th 2024
Podcast

Nausheen Ahmed, MD, discusses findings from a study supporting reduced monitoring windows for patients with lymphoma who receive CAR T-cell therapy.

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

177Lu-Dotatate Improves PFS in Recurrent Meningioma

Ariana Pelosci
October 1st 2024
Article

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

Hypofractionated RT After Mastectomy Is Noninferior to SOC in Breast Cancer

Hypofractionated RT After Mastectomy Is Noninferior to SOC in Breast Cancer

Ariana Pelosci
September 30th 2024
Article

Hypofractionated postmastectomy radiotherapy was noninferior to standard radiation in patients who underwent a mastectomy.